A lipoglycopeptide antibiotic for Gram-positive biofilm-related infections

  15 September 2022

Drug-resistant Gram-positive bacterial infections remain a critical concern, and new treatment modalities against them are needed in the clinic. Blaskovich et al. optimized a vancomycin-derived antibiotic bearing a membrane-targeting glycopeptide and demonstrated that this compound was effective in multiple mouse models of Gram-positive infections, including difficult-to-treat biofilms. The optimized compound was more potent than its parent, vancomycin, and had a low rate of resistance, suggesting that this candidate compound may warrant further development.

Author(s): MARK A. T. BLASKOVICH et al
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Your Biweekly Source for Global AMR Insights!

Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.

Don’t miss out on staying ahead in the global AMR movement—subscribe now!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed